4/A

FORM 4/A SUBMISSION

Company: Kalaris Therapeutics, Inc.
Filed: October 26, 2022
Period of Report: October 20, 2022
Accession Number: 0000899243-22-034263

View Document ↗ View on SEC.gov ↗